PTGX
Protagonist Therapeutics Inc
143.00$
-0.5%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +43.7% | +533.1% | +74.2% | -14.8% | +11.1% | +109.4% | +7.2% | -28.7% | +44.4% | +108.1% | -10.0% | |
| – | +43.3% | +486.0% | +81.3% | -8.9% | +5.7% | +117.2% | +8.0% | -28.7% | +46.3% | +66.4% | -2.4% | |
| – | -56.5% | +420.0% | +402.9% | -22.4% | -59.9% | +255.6% | +5.4% | +1.7% | +48.5% | -47.9% | +32.0% | |
| – | +27.9% | +550.8% | +85.6% | -10.5% | +3.2% | +129.9% | +6.9% | -27.4% | +43.9% | +22.6% | +35.4% | |
| – | +36.7% | +213.4% | -19.0% | +152.6% | +47.3% | -43.4% | +39.6% | -99.0% | +19,769.2% | +1,530.8% | -97.3% | |
| – | +12,530.0% | -705.9% | – | – | +124.2% | -17.1% | +113.9% | -101.1% | – | – | – | |
| – | +46.7% | -7.7% | +56.4% | -2.0% | +797.0% | -81.1% | +360.6% | -76.8% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +121.2% | +22.6% | +569.8% | -37.5% | +178.0% | -40.1% | +6.3% | -32.2% | -34.2% | +226.4% | -20.5% | |
| – | +131.6% | +105.9% | +561.3% | -38.5% | +35.4% | +13.7% | +9.4% | -29.2% | -31.8% | +122.8% | -4.1% | |
| – | – | – | – | – | +18.4% | +16.2% | +50.8% | +14.3% | -54.6% | -55.3% | +347.6% | |
| – | +257.3% | -6.7% | +8.1% | +354.3% | -51.1% | +10.2% | -48.0% | +127.5% | -78.8% | +109.2% | +230.6% | |
| – | – | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | +20.6% | -773.1% | – | – | – | +249.7% | +7.3% | -28.1% | +56.2% | +100.6% | -9.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +10.5% | +172.1% | +26.4% | +15.8% | +32.8% | +34.7% | +5.9% | +15.7% | +14.6% | -2.3% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.